Excerpt: “The Inflation Reduction Act (IRA) changes the way Medicare pays for prescription drugs. These changes will impact various stakeholders, including Medicare, Medicare enrollees, drug manufacturers, and others. We present a high-level approach for how to evaluate each IRA Medicare drug-related provision, including identification of key research questions and outcomes; the potential methods that can be used; and the challenges that may arise. We also describe the issues that were considered in the development of the evaluation framework. The framework presented here can be used to develop and implement a comprehensive evaluation of the IRA’s Medicare drug-related provisions.”
38,710 Entries
45 Added in Past 24 Hours
Share